Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5697 Target Snapshot

Egl nine homolog 1 · SINGLE PROTEIN · Homo sapiens

2,203Compounds
194Assays
4Approved Drugs
2,930.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Egl nine homolog 1 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9GZT9. Start with anemia (phenotype), then reuse UniProt Q9GZT9 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anemia (phenotype), then reuse UniProt Q9GZT9 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
anemia (phenotype)

Egl nine homolog 1 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Egl nine homolog 1 as ChEMBL target CHEMBL5697, mapped to UniProt Q9GZT9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Egl nine homolog 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5697
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9GZT9
Egl nine homolog 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Egl nine homolog 1 is the right protein anchor across sources, using UniProt Q9GZT9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anemia (phenotype) is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEgl nine homolog 1
UniProt AccessionQ9GZT9
Component TypeProtein
Sequence Length426 aa

Egl nine homolog 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Egl nine homolog 1, mapped to UniProt Q9GZT9. Sequence length is 426 aa.

Mapped IDQ9GZT9
Review nameEgl nine homolog 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Egl nine homolog 1 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block.

Approved-linked Approved
anemia (phenotype)
2 linked drugs · 2 direct · 2 efficacy
Linked drugMOLIDUSTAT
Linked drugVADADUSTAT
Approved-linked Approved
chronic kidney disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugENARODUSTAT
Linked drugVADADUSTAT
Approved-linked Approved
anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugVADADUSTAT
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugVADADUSTAT
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanemia (phenotype)
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
2
Phase III
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC502,860.0
KI5.0
EC5033.0
KD32.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2043325 9.7 IC50 0.2 Preclinical
CHEMBL2041193 9.7 IC50 0.2 Preclinical
CHEMBL2041192 9.7 IC50 0.2 Preclinical
CHEMBL2041190 9.7 IC50 0.2 Preclinical
CHEMBL2041186 9.7 IC50 0.2 Preclinical
CHEMBL2041185 9.7 IC50 0.2 Preclinical
CHEMBL2041184 9.7 IC50 0.2 Preclinical
CHEMBL2041182 9.7 IC50 0.2 Preclinical
CHEMBL2041175 9.7 IC50 0.2 Preclinical
CHEMBL2041169 9.7 IC50 0.2 Preclinical
Distribution

pChEMBL Value Distribution

256
5.0
205
5.5
303
6.0
352
6.5
543
7.0
235
7.5
205
8.0
59
8.5
32
9.0
12
9.5
pChEMBL
Approved Drugs

Approved Drugs

VADADUSTAT
CHEMBL3646221
Approved 2023
DAPRODUSTAT
CHEMBL3544988
Approved 2023
ROXADUSTAT
CHEMBL2338329
Approved 2021
Assay Landscape

Assay Landscape

194
Total Assays
1,965
Tested Compounds
1
Assay Types
Binding — 194 assays, 1,965 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 109 1,281 6.8
cell-based format 70 652 5.9
assay format 15 32 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine